CrystalGenomics Receives Approval for Phase 1 Clinical Trial of Fibrosis Drug Candidate ‘CG-750’

[Asia Economy Reporter Hyungsoo Park] CrystalGenomics announced on the 13th that it has received approval from the Ministry of Food and Drug Safety for the Phase 1 clinical trial of the fibrosis treatment drug candidate ‘CG-750’. The company will now officially begin developing CG-750 as a treatment for various fibrotic diseases, including idiopathic pulmonary fibrosis (IPF).

The Phase 1 trial is a multiple ascending dose (MAD) study conducted at Seoul National University Hospital involving 24 healthy adult males. The study will administer repeated oral doses of CG-750 capsules to evaluate pharmacokinetics, safety, and tolerability. The trial will also assess the potential for developing an oral formulation of the anticancer drug to improve medication convenience.

By developing an oral formulation, it is expected to enhance patient compliance and reduce economic burden. Patients will be able to continue treatment through oral medication in daily life without having to visit the hospital each time. In contrast, existing injectable drugs require patients to visit the hospital for intravenous administration, which is inconvenient.

CrystalGenomics selected the fibrosis field, which has significant unmet medical needs, as a target area and established its subsidiary Makaon in July last year. The company received an investment of 28 billion KRW. The goal is to increase the success rate of fibrosis drug development and shorten development time.

A representative from Makaon stated, “With reports of fibrosis occurring as a sequela of COVID-19, expectations for the development of treatments are higher than ever.”

This content was produced with the assistance of AI translation services.